drugset / Trial / NCT03364998

BAY94-9027 PK Study Comparing to Another Long Acting Product

NCT03364998

Phase 1 Completed 18 enrolled Bayer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare the pharmacokinetics of BAY94-9027 and Elocta after intravenous administration.

Timeline

Start
2017-11-30
Primary completion
2018-01-25
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Damoctocog Protein / enzyme biologic 60 iu/kg Intravenous
Subject Efmoroctocog Alfa Protein / enzyme biologic 60 iu/kg Intravenous

Indications